Acute and nine-month clinical outcomes after “suboptimal” coronary stenting : Results from the STent anti-thrombotic regimen study (STARS) registry

OBJECTIVES This registry collected the 30-day and 9-month clinical outcomes of patients whose coronary stent implantation was suboptimal, and compared them with the cohort of patients with “optimal” stenting in the randomized portion of the STent Anti-thrombotic Regimen Study (STARS) trial. BACKGROUND Although “optimal” stenting combined with an aspirin and ticlopidine regimen carries low (0.5%) incidence of subacute stent thrombosis, only limited dat are available for patients in whom stents are deployed suboptimally. METHODS In the STARS, 312 (15.9%) of 1,965 patients enrolled were excluded from participation in the randomized trial based on perceived “suboptimal” result of coronary stenting. Of these, 265 patients met prespecified criteri for suboptimal stenting, and were followed in parallel registry, which was compared with the randomized STARS optimal stenting cohort. The primary end point was 30-day composite of death, emergent target lesion revascularization, angiographic thrombosis of the target vessel without revascularization and nonfatal myocardial infarction (MI)unrelated to direct procedural complications. RESULTS Registry patients had similar frequency of the primary end point compared with the overall randomized cohort (3.0% vs. 2.2%), with this end point correlating to use of multiple stents, smaller final lumen diameter and absence of ticlopidine from the poststent regimen. Overall 30-day mortality (1.1% vs. 0.06%, p = 0.009) and periprocedural non-Q wave MI (8.7% vs. 4.2%, p = 0.003) were more frequent in registry patients, and appeared to be related to acute procedural complications. Clinical restenosis was significantly higher for registry patients (26.8% vs. 16.0%, p = 0.001), relating to greater prevalence of independent predictors such as smaller final lumen diameter and multiple stent use. CONCLUSIONS In the STARS registry, the inability to perform optimal stenting correlated with smaller final lumen diameter and longer stent length. With ticlopidine-containing regimens, the acute clinical results of “suboptimal” stent deployment are clinically acceptable, although they are not quite as good as those of optimal stenting using similar drug therapy.